Pelthos Therapeutics reported cash from operations of -$20.79M and free cash flow of -$20.99M for the quarter ended Jun 2026. This cash flow statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Net Income | -0.97M | -0.95M | -1.42M | -4.04M | -2.56M | -1.77M | -1.70M | -1.93M | -1.97M | -3.45M | -16.24M | -21.66M | -25.07M | -48.49M | |
| Share-based CompensationStock Comp. | 0.05M | 0.27M | 0.20M | 0.20M | 0.79M | 0.29M | 0.08M | 0.44M | 0.53M | 0.87M | 0.09M | 2.81M | 1.80M | 1.91M | 4.67M |
| Deferred Taxes | 7.85M | ||||||||||||||
| Asset Writedowns and ImpairmentWritedown | 0.79M | 0.26M | 0.93M | ||||||||||||
| Cash from OperationsCash from Ops. | -0.17M | -0.19M | -0.26M | -0.36M | -1.99M | -2.95M | -0.18M | -0.67M | -0.63M | -0.45M | -15.26M | -6.25M | -13.13M | -20.79M | |
| Depreciation, Depletion & Amortization | |||||||||||||||
| Amortizatization of IntangiblesAmort. of Intangibles | 0.03M | 0.02M | 0.02M | 0.12M | 0.61M | 0.01M | 0.08M | 0.09M | 0.17M | 1.06M | 1.08M | 1.08M | 2.04M | ||
| Change in Working Capital | |||||||||||||||
| Change in ReceivablesChange Receivables | 2.84M | 5.62M | |||||||||||||
| Change in InventoryChange Inventory | -0.16M | -1.37M | |||||||||||||
| Change in Account PayablesChange Payables | 0.62M | 0.71M | 2.40M | 0.93M | -2.67M | 3.16M | 2.82M | ||||||||
| Change in Accured ExpensesChange Accured Exp. | 0.37M | 0.18M | 0.62M | 0.46M | -0.15M | -1.33M | 1.20M | 0.02M | 2.67M | 3.47M | -1.91M | 6.40M | |||
| Other Working Capital ChangesOther WC Changes | -0.24M | -0.42M | |||||||||||||
| Investing Activities | |||||||||||||||
| Capital ExpendituresCapex | 0.19M | 0.20M | |||||||||||||
| Cash from Investing ActivitiesCash from Investing | 2.76M | -8.00M | -0.19M | -0.20M | |||||||||||
| Financing Activities | |||||||||||||||
| Other financing activitiesOther financing | 0.12M | ||||||||||||||
| Cash from Financing ActivitiesCash from Financing | 0.17M | 0.23M | 0.20M | 0.43M | 5.67M | 1.59M | -0.97M | -0.07M | 0.25M | 0.38M | 26.69M | 18.02M | 27.52M | 27.52M | |
| Change in Capital Stock | |||||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 0.16M | 0.06M | 0.68M | 0.01M | |||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 5.97M | ||||||||||||||
| Additional items | |||||||||||||||
| Change in Cash | -0.01M | 0.03M | -0.06M | 0.07M | 3.67M | -1.37M | -1.15M | -0.74M | -0.38M | -0.07M | 14.19M | 3.77M | 14.20M | 6.54M | |
| Free Cash FlowFCF | -0.17M | -0.19M | -0.26M | -0.36M | -1.99M | -2.95M | -0.18M | -0.67M | -0.63M | -0.45M | -15.26M | -6.25M | -13.32M | -20.99M | |
| Net Cash FlowNCF | -0.01M | 0.03M | -0.06M | 0.07M | 3.67M | -1.37M | -1.15M | -0.74M | -0.38M | -0.07M | 14.19M | 3.77M | 14.20M | 6.54M |